We used a flow cytometry technique, the "FOG" method ( @entity406 and @entity6072 ), to investigate the expression of activation antigens, i.e., @entity404 , @entity7527 , @entity2902 , HLA-DR, and the EG2 epitope of eosinophilic cationic protein, on peripheral blood eosinophils (PBEs) in @entity1778 @entity1 who had developed @entity2132 ( @entity2132 ) with @entity1712 after allogeneic bone marrow transplantation (alloBMT) or leukocyte buffy coat infusion. A comparative analysis was performed in transplanted @entity1 not affected by @entity2132 and in other conditions commonly associated with peripheral @entity1712 , i.e., @entity1199 immunotherapy and @entity566 . @entity2902 , recognizing the p55 subunit of IL-2 receptor, was detected in all @entity1 with @entity2132 except two who, at the onset of @entity1712 , were already receiving @entity1667 intravenously. The specificity of our findings is confirmed by the absence of reactivity with anti- @entity2902 mAb in PBEs from transplanted @entity1 not affected by @entity2132 . Interestingly, the expression of @entity2902 progressively declined after @entity134 therapy. @entity2902 was also expressed after rhIL-2 administration, probably reflecting analogous mechanisms of eosinophil activation. No @entity2132 or rhIL-2-treated @entity1 showed reactivity with anti- @entity404 , @entity7527 , or HLA-DR. @entity2902 and @entity7527 antigens were detected in 29% and 36% of @entity56 @entity1 only. The accessibility of the EG2 epitope was significantly enhanced in all study groups compared with controls. In vitro activation of normal eosinophils with @entity1359 upregulated @entity6460 and EG2 expression but failed to induce the @entity2902 antigen, suggesting that selective activating stimuli may be required. The functional significance of in vivo @entity2902 expression and the role of activated PBEs in the development of cellular and cytokine-mediated tissue destructive processes in @entity2132 remain to be clarified.

Immunophenotypic profile of peripheral blood eosinophils in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1712 :: ('MESH:D004802', 'Disease') :: ['eosinophilia'] @entity1667 :: ('MESH:D008775', 'Chemical') :: ['methylprednisolone'] @entity6460 :: ('928', 'Gene') :: ['CD9'] @entity404 :: ('920', 'Gene') :: ['CD4'] @entity6072 :: ('MESH:C018619', 'Chemical') :: ['octylglucopyranoside'] @entity566 :: ('MESH:D006967', 'Disease') :: ['allergy'] @entity406 :: ('MESH:D005557', 'Chemical') :: ['formaldehyde'] @entity1359 :: ('CHEBI:37537', 'Chemical') :: ['phorbol 12-myristate 13-acetate'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemic'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['acute graft-vs.-host disease', 'aGVHD'] @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic'] @entity2902 :: ('3559', 'Gene') :: ['CD25'] @entity1199 :: ('3558', 'Gene') :: ['interleukin (IL)-2'] @entity7527 :: ('2208', 'Gene') :: ['CD23']
@entity2132 :: (MESH:D006086,Disease) :: ['acute graft-vs.-host disease']
